{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:04:38Z","timestamp":1784761478412,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"DOI":"10.1007\/s11096-025-02048-1","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T12:34:21Z","timestamp":1762950861000},"page":"257-265","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness of omadacycline versus moxifloxacin as the initial treatment for community-acquired bacterial pneumonia in China"],"prefix":"10.1007","volume":"48","author":[{"given":"Xiuling","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guijun","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiang","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"15","key":"2048_CR1","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1001\/jama.2024.14796","volume":"332","author":"VM Vaughn","year":"2024","unstructured":"Vaughn VM, Dickson RP, Horowitz JK, et al. Community-acquired pneumonia: a review. JAMA. 2024;332(15):1282\u201395. https:\/\/doi.org\/10.1001\/jama.2024.14796.","journal-title":"JAMA"},{"issue":"17","key":"2048_CR2","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1056\/NEJMc2310748","volume":"389","author":"LT Keng","year":"2023","unstructured":"Keng LT, Yang HC. Community-acquired pneumonia. N Engl J Med. 2023;389(17):1633. https:\/\/doi.org\/10.1056\/NEJMc2310748.","journal-title":"N Engl J Med"},{"issue":"52","key":"2048_CR3","doi-asserted-by":"publisher","first-page":"8362","DOI":"10.1016\/j.vaccine.2020.11.004","volume":"38","author":"Y Sun","year":"2020","unstructured":"Sun Y, Li H, Pei Z, et al. Incidence of community-acquired pneumonia in urban China: a national population-based study. Vaccine. 2020;38(52):8362\u201370. https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.004.","journal-title":"Vaccine"},{"issue":"1","key":"2048_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1053\/j.ro.2021.10.006","volume":"57","author":"K Delijani","year":"2022","unstructured":"Delijani K, Price MC, Little BP. Community and hospital acquired pneumonia. Semin Roentgenol. 2022;57(1):3\u201317. https:\/\/doi.org\/10.1053\/j.ro.2021.10.006.","journal-title":"Semin Roentgenol"},{"issue":"6","key":"2048_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e28008","volume":"10","author":"AM Seid","year":"2024","unstructured":"Seid AM, Tadesse W, Menza M. Bacterial etiology of community-acquired pneumonia among adult patients in Ethiopia: a systematic review and meta-analysis. Heliyon. 2024;10(6):e28008. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e28008.","journal-title":"Heliyon"},{"issue":"3","key":"2048_CR6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/14787210.2023.2174100","volume":"21","author":"G Sakoulas","year":"2023","unstructured":"Sakoulas G, Nowak M, Geriak M. Omadacycline in treating community-based infections: a review and expert perspective. Expert Rev Anti-Infect Ther. 2023;21(3):255\u201365. https:\/\/doi.org\/10.1080\/14787210.2023.2174100.","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"6","key":"2048_CR7","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJMoa1800201","volume":"380","author":"R Stets","year":"2019","unstructured":"Stets R, Popescu M, Gonong JR, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380(6):517\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1800201.","journal-title":"N Engl J Med"},{"issue":"2","key":"2048_CR8","doi-asserted-by":"publisher","first-page":"e0108724","DOI":"10.1128\/aac.01087-24","volume":"69","author":"TM File Jr","year":"2025","unstructured":"File TM Jr, Ramirez JA, Wilde AM. New perspectives on antimicrobial agents: omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus on M. abscessus). Antimicrob Agents Chemother. 2025;69(2):e0108724. https:\/\/doi.org\/10.1128\/aac.01087-24.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2048_CR9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3760\/cma.j.issn.1001-0939.2016.04.005.Chinese","volume":"39","author":"Chinese Medical Association Respiratory Branch","year":"2016","unstructured":"Chinese Medical Association Respiratory Branch. Chinese guidelines for the diagnosis and treatment of community-acquired pneumonia in adults (2016). Chin J Tubere Respir Dis. 2016;39(4):253\u201379. https:\/\/doi.org\/10.3760\/cma.j.issn.1001-0939.2016.04.005.Chinese.","journal-title":"Chin J Tubere Respir Dis"},{"key":"2048_CR10","doi-asserted-by":"publisher","unstructured":"Emergency Medicine Branch of Chinese Medical Association. Expert consensus group on emergency diagnosis and Treatment of community-acquired pneumonia in elderly people in China. [Expert Consensus on the Emergency Diagnosis and Treatment of Community-Acquired Pneumonia in Elderly Patients in China. Chin J Emerg Med. 2023;32(10):1319\u2013327. https:\/\/doi.org\/10.3760\/cma.j.issn.1671-0282.2023.10.005.Chinese.","DOI":"10.3760\/cma.j.issn.1671-0282.2023.10.005.Chinese"},{"issue":"9","key":"2048_CR11","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.3969\/j.issn.1005-9202.2019.09.028.Chinese","volume":"39","author":"JZ Yu","year":"2019","unstructured":"Yu JZ, Hai PZ, Kai FZ, et al. Clinical effect of moxifloxacin in the treatment of patients with clinical community-acquired pneumonia. Chin J Gerontol. 2019;39(9):2129\u201332. https:\/\/doi.org\/10.3969\/j.issn.1005-9202.2019.09.028.Chinese.","journal-title":"Chin J Gerontol"},{"key":"2048_CR12","doi-asserted-by":"publisher","first-page":"4833","DOI":"10.2147\/IDR.S540124","volume":"18","author":"S Liang","year":"2025","unstructured":"Liang S, Wen YH, Zhang ZH, et al. Efficacy of lefamulin for community-acquired bacterial pneumonia (CABP) patients: pooled analysis of the lefamulin evaluation against pneumonia (LEAP) 1, LEAP 2 and LEAP China trials. Infect Drug Resist. 2025;18:4833\u201345. https:\/\/doi.org\/10.2147\/IDR.S540124.","journal-title":"Infect Drug Resist"},{"key":"2048_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lansea.2025.100666","volume":"41","author":"H Pophale","year":"2025","unstructured":"Pophale H, Gupta M, Llorens L, et al. Efficacy and safety of a 3-day once-daily regimen of oral nafithromycin in comparison to oral moxifloxacin for the treatment of community-acquired bacterial pneumonia in adults: a phase III, randomized, double-blind controlled trial. Lancet Reg Health. 2025;41:100666. https:\/\/doi.org\/10.1016\/j.lansea.2025.100666.","journal-title":"Lancet Reg Health"},{"issue":"5","key":"2048_CR14","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.resinv.2025.06.014","volume":"63","author":"H Mukae","year":"2025","unstructured":"Mukae H, Iwanaga N, Horita N, et al. The JRS guideline for the management of pneumonia in adults 2024. Respir Investig. 2025;63(5):811\u201328. https:\/\/doi.org\/10.1016\/j.resinv.2025.06.014.","journal-title":"Respir Investig"},{"issue":"7","key":"2048_CR15","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","volume":"200","author":"JP Metlay","year":"2019","unstructured":"Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the american thoracic society and infectious diseases society of America. Am J Respir Crit Care Med. 2019;200(7):e45-67. https:\/\/doi.org\/10.1164\/rccm.201908-1581ST.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"2048_CR16","doi-asserted-by":"publisher","first-page":"743","DOI":"10.12788\/jhm.3444","volume":"15","author":"CD Jackson","year":"2020","unstructured":"Jackson CD, Burroughs-Ray DC, Summers NA. Clinical guideline highlights for the hospitalist: 2019 American Thoracic Society\/Infectious Diseases Society of America update on community-acquired pneumonia. J Hosp Med. 2020;15(12):743\u20135. https:\/\/doi.org\/10.12788\/jhm.3444.","journal-title":"J Hosp Med"},{"issue":"9","key":"2048_CR17","doi-asserted-by":"publisher","first-page":"e2607","DOI":"10.1093\/cid\/ciaa860","volume":"73","author":"SM Bart","year":"2021","unstructured":"Bart SM, Nambiar S, Gopinath R, et al. Concordance of early and late end points for community-acquired bacterial pneumonia trials. Clin Infect Dis. 2021;73(9):e2607\u201312. https:\/\/doi.org\/10.1093\/cid\/ciaa860.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2048_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa209","volume":"7","author":"TP Lodise","year":"2020","unstructured":"Lodise TP, Colman S, Alexander E, et al. Health-related quality of life as measured by the 12-item short-form survey among adults with community-acquired bacterial pneumonia who received either lefamulin or moxifloxacin in 2 phase III randomized, double-blind, double-dummy clinical trials. Open Forum Infect Dis. 2020;7(6):ofaa209. https:\/\/doi.org\/10.1093\/ofid\/ofaa209.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"2048_CR19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.52314","volume":"2","author":"S Tingsg\u00e5rd","year":"2024","unstructured":"Tingsg\u00e5rd S, Bastrup Israelsen S, J\u00f8rgensen HL. Early switch from intravenous to oral antibiotics for patients with uncomplicated Gram-negative bacteremia. JAMA Netw Open. 2024;2(1):e2352314. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.52314.","journal-title":"JAMA Netw Open"},{"key":"2048_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dym062","volume":"36","author":"D Caldwell","year":"2007","unstructured":"Caldwell D. Decision modelling for health economic evaluation. A Briggs, M Sculpher, K Claxton. Int J Epidemiol. 2007;36:476\u20137. https:\/\/doi.org\/10.1093\/ije\/dym062.","journal-title":"Int J Epidemiol"},{"issue":"4","key":"2048_CR21","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10198-021-01384-z","volume":"23","author":"D Cai","year":"2022","unstructured":"Cai D, Shi S, Jiang S, et al. Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life. Eur J Health Econ. 2022;23(4):607\u201315. https:\/\/doi.org\/10.1007\/s10198-021-01384-z.","journal-title":"Eur J Health Econ"},{"issue":"8","key":"2048_CR22","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s10096-016-2661-5","volume":"35","author":"D Rodriguez-Pardo","year":"2016","unstructured":"Rodriguez-Pardo D, Pigrau C, Campany D, et al. Effectiveness of sequential intravenous-to-oral antibiotic switch therapy in hospitalized patients with gram-positive infection: the SEQUENCE cohort study. Eur J Clin Microbiol Infect Dis. 2016;35(8):1269\u201376. https:\/\/doi.org\/10.1007\/s10096-016-2661-5.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"2048_CR23","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1186\/s12889-021-11882-7","volume":"21","author":"N Wang","year":"2021","unstructured":"Wang N, Yang Y, Xu L, et al. Influence of Chinese national centralized drug procurement on the price of policy-related drugs: an interrupted time series analysis. BMC Public Health. 2021;21(1):1883. https:\/\/doi.org\/10.1186\/s12889-021-11882-7.","journal-title":"BMC Public Health"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02048-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-02048-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02048-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:18:53Z","timestamp":1768972733000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-02048-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["2048"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-02048-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7610117\/v1","asserted-by":"object"}]},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"14 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethics approval was not required as this was a pharmacoeconomic study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}